Head-to-head comparison
| Property | MK-677 | Ipamorelin |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Unregulated | Reclassification Pending |
| Primary Route | oral | subcutaneous |
| Half-life | ~24 hours | ~2 hours |
| Mol. Weight | 528.67 Da | 711.85 Da |
| Side Effects | Increased appetite / intense hunger, Water retention and edema, Insulin resistance (glucose elevation) | Headache, Flushing, Injection site pain |
Key differences
- Administration: MK-677 is orally active (pill/capsule form); ipamorelin requires subcutaneous or intramuscular injection.
- Chemical class: MK-677 is a non-peptide ghrelin mimetic (small molecule); ipamorelin is a pentapeptide (5 amino acids).
- Selectivity: Ipamorelin is highly selective for GH release with minimal impact on cortisol, prolactin, and appetite; MK-677 increases appetite, cortisol, and prolactin to a greater degree.
- Duration of action: MK-677 has a 24-hour duration of action supporting once-daily dosing; ipamorelin has a 2-hour half-life requiring multiple daily doses for sustained elevation.
- IGF-1 elevation: MK-677 produces sustained IGF-1 elevation (up to 40% increase over baseline in studies); ipamorelin produces more transient IGF-1 changes.
- Appetite effects: MK-677 significantly increases appetite (a ghrelin-pathway side effect); ipamorelin has minimal appetite stimulation due to its receptor selectivity.
- Clinical data: MK-677 has published human clinical trials including studies in elderly subjects; ipamorelin has Phase II clinical data but less published human research.
The verdict
The choice depends on priorities. MK-677 offers the convenience of oral dosing and sustained GH/IGF-1 elevation, but comes with increased appetite, potential water retention, and broader hormonal effects. Ipamorelin offers cleaner GH selectivity with minimal off-target effects but requires injection. For researchers prioritizing purity of GH stimulation, ipamorelin is typically preferred; for convenience and sustained IGF-1 elevation, MK-677 is more practical.
Frequently asked questions
MK-677 (ibutamoren) is technically not a peptide—it is a non-peptide, orally active ghrelin receptor mimetic (a small molecule). It is frequently discussed alongside peptide secretagogues because it acts on the same ghrelin receptor pathway to stimulate growth hormone release.
Yes, MK-677 significantly increases appetite as a downstream effect of ghrelin receptor activation. Ipamorelin is notably more selective and produces minimal appetite stimulation, which is one of its key advantages.
Both act on the ghrelin receptor pathway, so combining them would likely produce redundant stimulation rather than true synergy. Ipamorelin is more commonly paired with a GHRH analog like CJC-1295 for complementary GH release through two different pathways.
MK-677 produces more sustained IGF-1 elevation due to its 24-hour duration of action, with studies showing up to 40% increases over baseline. Ipamorelin produces more transient GH pulses with correspondingly shorter IGF-1 elevations.
MK-677 can increase fasting blood glucose and decrease insulin sensitivity in some individuals, particularly with long-term use. This is less commonly reported with ipamorelin. Individuals with insulin resistance or diabetes risk factors should be aware of this effect.